NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free BCDA Stock Alerts $0.38 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.38▼$0.3950-Day Range$0.36▼$0.5852-Week Range$0.32▼$2.92Volume74,865 shsAverage Volume155,866 shsMarket Capitalization$10.21 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioCardia alerts: Email Address BioCardia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside952.9% Upside$4.00 Price TargetShort InterestHealthy1.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 3 Articles This WeekInsider TradingAcquiring Shares$50,942 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.42) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector2491st out of 5,424 stocksBiological Products, Except Diagnostic Industry346th out of 909 stocks 3.3 Analyst's Opinion Consensus RatingBioCardia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioCardia has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.01% of the outstanding shares of BioCardia have been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCardia has recently decreased by 49.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCDA. Previous Next 1.7 News and Social Media Coverage News SentimentBioCardia has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioCardia this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,942.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders23.90% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.57% of the stock of BioCardia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BioCardia are expected to decrease in the coming year, from ($0.42) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About BioCardia Stock (NASDAQ:BCDA)BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.Read More BCDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCDA Stock News HeadlinesMay 1, 2024 | finance.yahoo.comBioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesMay 1, 2024 | globenewswire.comBioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.May 1, 2024 | americanbankingnews.comBioCardia (NASDAQ:BCDA) versus Valneva (NASDAQ:VALN) Critical SurveyApril 25, 2024 | globenewswire.comBioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortApril 1, 2024 | finance.yahoo.comBioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsMarch 29, 2024 | finance.yahoo.comBioCardia Full Year 2023 Earnings: Misses ExpectationsMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.March 28, 2024 | benzinga.comPreview: BioCardia's EarningsMarch 28, 2024 | markets.businessinsider.comBioCardia is about to announce its earnings — here's what to expectMarch 28, 2024 | finance.yahoo.comQ4 2023 BioCardia Inc Earnings CallMarch 27, 2024 | benzinga.comBioCardia: Q4 Earnings InsightsMarch 27, 2024 | globenewswire.comBioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsMarch 20, 2024 | money.usnews.comBioCardia Inc.March 20, 2024 | globenewswire.comBioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024March 13, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipMarch 13, 2024 | globenewswire.comBioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipMarch 12, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyMarch 12, 2024 | msn.comBioCardia spikes after Medicare coverage for cell therapy trialMarch 12, 2024 | globenewswire.comBioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyMarch 4, 2024 | markets.businessinsider.comBioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure TrialMarch 4, 2024 | globenewswire.comBioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart FailureFebruary 27, 2024 | finance.yahoo.comBCDA Mar 2024 1.500 callFebruary 17, 2024 | finance.yahoo.comBCDA Aug 2024 0.500 callFebruary 17, 2024 | finance.yahoo.comBCDA Mar 2024 0.500 callFebruary 10, 2024 | msn.comBioCardia Inc Secures Funding Through Private PlacementSee More Headlines Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/04/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BCDA CUSIPN/A CIK925741 Webwww.biocardia.com Phone(650) 226-0120Fax310-861-5299Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+952.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,570,000.00 Net Margins-2,425.79% Pretax Margin-2,425.79% Return on Equity-3,638.68% Return on Assets-228.55% Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$480,000.00 Price / Sales21.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-5.43Miscellaneous Outstanding Shares26,870,000Free Float20,447,000Market Cap$10.21 million OptionableOptionable Beta1.47 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Peter A. Altman Ph.D. (Age 57)CEO, President & Director Comp: $515.51kMr. David McClung (Age 61)Chief Financial Officer Comp: $370.86kMr. Edward M. Gillis (Age 62)Senior Vice President of Devices Comp: $263.1kKey CompetitorsChromocell TherapeuticsNYSE:CHROOrganovoNASDAQ:ONVOCoeptis TherapeuticsNASDAQ:COEPInhibikase TherapeuticsNYSE:IKTGenetic TechnologiesNASDAQ:GENEView All CompetitorsInsidersPeter AltmanBought 2,750 shares on 4/19/2024Total: $1,017.50 ($0.37/share)Peter AltmanBought 500 shares on 3/28/2024Total: $195.00 ($0.39/share)Peter AltmanBought 108,108 shares on 2/13/2024Total: $49,729.68 ($0.46/share)Phillip Md Et Al FrostSold 129,802 sharesTotal: $55,814.86 ($0.43/share)Peter AltmanBought 6,200 shares on 5/26/2023Total: $9,920.00 ($1.60/share)View All Insider Transactions BCDA Stock Analysis - Frequently Asked Questions Should I buy or sell BioCardia stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BCDA shares. View BCDA analyst ratings or view top-rated stocks. What is BioCardia's stock price target for 2024? 2 equities research analysts have issued 12-month price targets for BioCardia's stock. Their BCDA share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 952.9% from the stock's current price. View analysts price targets for BCDA or view top-rated stocks among Wall Street analysts. How have BCDA shares performed in 2024? BioCardia's stock was trading at $0.6642 at the start of the year. Since then, BCDA stock has decreased by 42.8% and is now trading at $0.3799. View the best growth stocks for 2024 here. Are investors shorting BioCardia? BioCardia saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 271,200 shares, a decline of 49.4% from the March 31st total of 535,900 shares. Based on an average daily trading volume, of 345,100 shares, the short-interest ratio is presently 0.8 days. View BioCardia's Short Interest. When is BioCardia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BCDA earnings forecast. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) posted its earnings results on Wednesday, March, 27th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.20 million. BioCardia had a negative net margin of 2,425.79% and a negative trailing twelve-month return on equity of 3,638.68%. When did BioCardia's stock split? Shares of BioCardia reverse split on the morning of Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), RecycLiCo Battery Materials (AMY) and When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. Who are BioCardia's major shareholders? BioCardia's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Mcclung, Peter Altman and Phillip Md Et Al Frost. View institutional ownership trends. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCDA) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCUrgent Nvidia WarningAltimetryGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
